MA39048B1 - Nouveaux inhibiteurs de la dgat2 - Google Patents

Nouveaux inhibiteurs de la dgat2

Info

Publication number
MA39048B1
MA39048B1 MA39048A MA39048A MA39048B1 MA 39048 B1 MA39048 B1 MA 39048B1 MA 39048 A MA39048 A MA 39048A MA 39048 A MA39048 A MA 39048A MA 39048 B1 MA39048 B1 MA 39048B1
Authority
MA
Morocco
Prior art keywords
dgat2
new inhibitors
compounds
methods
inhibitors
Prior art date
Application number
MA39048A
Other languages
English (en)
Other versions
MA39048A1 (fr
Inventor
Nicholas Paul Camp
Manisha Naik
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52016867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39048(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA39048A1 publication Critical patent/MA39048A1/fr
Publication of MA39048B1 publication Critical patent/MA39048B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de la formule ci-dessous : (i) où r désigne h ou -ch3; des méthodes pour traiter des patients atteints d'hypertriglycéridémie et de maladies cardiovasculaires, y compris la dyslipidémie et l'athérosclérose, ainsi que des procédés pour préparer lesdits composés.
MA39048A 2013-11-25 2014-11-19 Nouveaux inhibiteurs de la dgat2 MA39048B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361908339P 2013-11-25 2013-11-25
PCT/US2014/066339 WO2015077299A1 (fr) 2013-11-25 2014-11-19 Nouveaux inhibiteurs de la dgat2

Publications (2)

Publication Number Publication Date
MA39048A1 MA39048A1 (fr) 2017-05-31
MA39048B1 true MA39048B1 (fr) 2018-04-30

Family

ID=52016867

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39048A MA39048B1 (fr) 2013-11-25 2014-11-19 Nouveaux inhibiteurs de la dgat2

Country Status (24)

Country Link
US (1) US9073901B2 (fr)
EP (1) EP3074381B1 (fr)
JP (1) JP6155395B2 (fr)
KR (1) KR20160072252A (fr)
CN (1) CN105764889B (fr)
AP (1) AP2016009230A0 (fr)
AR (1) AR098394A1 (fr)
AU (1) AU2014353109B2 (fr)
CA (1) CA2928468A1 (fr)
CL (1) CL2016001172A1 (fr)
CR (1) CR20160216A (fr)
DO (1) DOP2016000120A (fr)
EA (1) EA201690847A1 (fr)
ES (1) ES2695302T3 (fr)
HK (1) HK1223367A1 (fr)
IL (1) IL245245A0 (fr)
MA (1) MA39048B1 (fr)
MX (1) MX2016006665A (fr)
NZ (1) NZ719444A (fr)
PE (1) PE20161099A1 (fr)
PH (1) PH12016500963A1 (fr)
TN (1) TN2016000146A1 (fr)
TW (1) TW201609668A (fr)
WO (1) WO2015077299A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6413032B2 (ja) * 2015-05-20 2018-10-24 イーライ リリー アンド カンパニー 新規ｄｇａｔ２阻害剤
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CA3147573A1 (fr) 2019-07-17 2021-01-21 2692372 Ontario, Inc. Derives de benzenesulfonamide et leurs utilisations
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
WO2021236405A1 (fr) 2020-05-18 2021-11-25 Merck Sharp & Dohme Corp. Nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2
TW202229243A (zh) 2020-10-08 2022-08-01 美商默沙東藥廠 作為新穎二醯基甘油酯o-醯基轉移酶2抑制劑之苯并咪唑酮衍生物的製備
AR123701A1 (es) 2020-10-08 2023-01-04 Merck Sharp & Dohme Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2
WO2022106897A2 (fr) 2020-11-20 2022-05-27 2692372 Ontario, Inc. Procédés et composition pour effectuer des modifications de kras
EP4267135A4 (fr) 2020-12-22 2024-05-15 Merck Sharp & Dohme LLC Préparation de dérivés de tétrahydroindazole en tant que nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2
US20250066337A1 (en) 2021-08-26 2025-02-27 Pfizer Inc. Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide
KR20250107282A (ko) 2022-12-02 2025-07-11 머크 샤프 앤드 돔 엘엘씨 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 융합된 아졸 유도체의 제조

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053363A2 (fr) 2001-12-19 2003-07-03 Millennium Pharmaceuticals, Inc. Membres de la famille des diacylglycerol-acyltransferases 2 (dgat2) et leurs utilisations
EP1534074A4 (fr) 2002-07-18 2008-01-09 Merck & Co Inc Polytherapie pour le traitement de l'obesite
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
PL1756084T3 (pl) * 2004-06-04 2009-06-30 Arena Pharm Inc Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie zaburzeń z metabolizmem związanych
US20080200376A1 (en) 2004-10-29 2008-08-21 Maccoss Malcolm Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction
WO2008129080A1 (fr) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibiteurs de protéine kinases
WO2011078102A1 (fr) * 2009-12-22 2011-06-30 第一三共株式会社 Nouveau dérivé de phénoxypyrimidine
EP2515901A2 (fr) 2009-12-22 2012-10-31 The Administrators of the Tulane Educational Fund Compositions et procédés de traitement de l'obésité et du diabète
US20130079345A1 (en) * 2010-03-22 2013-03-28 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
US9085562B2 (en) * 2011-03-03 2015-07-21 Vanderbilt University 6-alkyl-N-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
EP2561867A1 (fr) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Inhibiteurs de CDK9 pour le traitement du carcinome de la ligne médiane
EP2562265A1 (fr) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Sensibilité à des inhibiteurs sélectifs de CDK9
EA201400990A1 (ru) 2012-04-06 2015-01-30 Пфайзер Инк. Ингибиторы диацилглицеринацилтрансферазы 2

Also Published As

Publication number Publication date
KR20160072252A (ko) 2016-06-22
CR20160216A (es) 2016-06-27
AR098394A1 (es) 2016-05-26
JP2016539115A (ja) 2016-12-15
DOP2016000120A (es) 2016-06-15
CN105764889A (zh) 2016-07-13
EP3074381A1 (fr) 2016-10-05
EA201690847A1 (ru) 2016-09-30
US20150148358A1 (en) 2015-05-28
ES2695302T3 (es) 2019-01-03
WO2015077299A1 (fr) 2015-05-28
CL2016001172A1 (es) 2016-12-09
IL245245A0 (en) 2016-06-30
PE20161099A1 (es) 2016-10-22
EP3074381B1 (fr) 2018-07-04
AU2014353109B2 (en) 2017-02-02
MA39048A1 (fr) 2017-05-31
AP2016009230A0 (en) 2016-05-31
CN105764889B (zh) 2018-01-02
NZ719444A (en) 2017-12-22
PH12016500963A1 (en) 2016-06-20
JP6155395B2 (ja) 2017-06-28
TW201609668A (zh) 2016-03-16
HK1223367A1 (zh) 2017-07-28
US9073901B2 (en) 2015-07-07
AU2014353109A1 (en) 2016-05-12
MX2016006665A (es) 2016-07-26
CA2928468A1 (fr) 2015-05-28
TN2016000146A1 (en) 2017-10-06

Similar Documents

Publication Publication Date Title
MA39048B1 (fr) Nouveaux inhibiteurs de la dgat2
MA40301A1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
MA44820A1 (fr) Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
EA201391290A1 (ru) Гетероциклические модуляторы синтеза липидов
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
MA35351B1 (fr) Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.
AR088983A1 (es) Procedimiento para la preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
MX2018007075A (es) Compuestos policiclicos como inhibidores de tirosina quinasa de bruton.
MA35016B1 (fr) Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt
EA201690844A1 (ru) Ингибиторы gsk-3
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
MA40895A (fr) Synthèse de copanlisib et son sel de dichlorhydrate
IN2012DN00695A (fr)
EA201590561A1 (ru) Пролекарства аминохиназолинового ингибитора киназы
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
EA201792187A1 (ru) Производные азахиназолин карбоксамида
JO3264B1 (ar) مركبات ازيتيدينيل أوكسي فينيل بيروليدين
JO3248B1 (ar) عملية لتحضير إنزيمات مثبطة من نوع c-fms
MX2019011261A (es) Compuestos de isoxazol carboxamida y sus usos.
IN2015DN00659A (fr)
IN2012DN06286A (fr)
MA39756A (fr) Nouveau sel de l'ivabradine et son procédé de préparation
EA201300141A1 (ru) Алкилзамещенные 3-гидроксипиридины для лечения депрессии